Loading company…
Wuxi Kejin Biotechnology develops anticancer drugs and cellular therapies for rare diseases.
Founded in Wuxi in 2022, Wuxi Kejin Biotechnology researches and develops anticancer drugs and cellular therapies for blood disorders, including pyruvate kinase deficiency. The company uses its CRISPR 2.0 gene editing platform with an AAV delivery system. Its founders include CEO Dr. Haifeng Wang and Chief Scientific Officer Prof. Jose Carlos Segovia.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in